POXEL : Communiqué du 24/11

BCF64

24 nov. 2025 •07:51

Poxel's recovery plan has been finalised:
Main objectives:
accelerating commercial development and partnership-seeking activities for Imeglimine outside Japan, PXL 770 and PXL 065,
significantly reducing the Company's costs, and
clearing the Company's liabilities.
It was developed with the support of its long-standing financial partner IPF.
IPF and IRIS have committed to providing the Company with new financing of up to €11.25 million (including amounts drawn during the observation period) to turn it around.
The draft plan remains subject to the decision of the Commercial Court (Tribunal des activités économiques) of Lyon.
As a reminder, shareholders will meet at the annual general meeting on 11 December 2025 to approve, in particular:
Poxel's 2024 annual and consolidated financial statements,
the listing of Poxel shares on Euronext Growth, and
the delegations relating to capital transactions aimed at carrying out:
a capital increase with preferential subscription rights, open to all shareholders,
a capital increase reserved for IPF, and
enable the new IRIS financing.
The implementation of these various financing and capital transactions is an essential condition of the recovery plan to maintain Poxel's business and avoid judicial liquidation.
Organisation of a webinar open to all shareholders to present the draft recovery plan and future development prospects, to be held on next 26 November.